Chairman John Moolenaar (R-MI) of the House Select Committee on China (SCC) and Congressman Chris Smith (R-NJ), Co-Chair of the Congressional-Executive Commission on China (CECC), sent a letter to Acting Attorney General Todd Blanche.
Chairman John Moolenaar of the Select Committee on China sent a letter to Ted Leonsis, the Chairman and CEO of Monumental Sports & Entertainment (MSE) and the owner of the Washington Capitals and Washington Wizards, requesting information regarding the nature of the partnership between MSE and Alibaba. The letter comes after last month’s decision by the Pentagon adding Alibaba to its updated list of companies linked to the Chinese military operating in the U.S.
Chairman John Moolenaar of the Select Committee on China has sent a letter to Bristol Myers Squibb Chief Executive Officer Chris Boerner asking the pharmaceutical company to provide more information about the company's clinical drug trials in China.
Chairman John Moolenaar of the Select Committee on China (SCC) has sent a letter to Eli Lilly and Company Chief Executive Officer David Ricks asking the pharmaceutical company to provide more information about the company's clinical drug trials in China.
Chairman John Moolenaar of the Select Committee on China has sent a letter to Merck Chief Executive Officer Robert Davis asking the pharmaceutical company to provide more information about the company's clinical drug trials in China.
Chairman John Moolenaar of the Select Committee on China (SCC) has sent a letter to AbbVie Chief Executive Officer Robert Michael asking the pharmaceutical company to provide more information about the company's clinical drug trials in China.
Chairman John Moolenaar of the Select Committee on China has sent a letter to Pfizer Chief Executive Officer Dr. Albert Bourla asking the pharmaceutical company to provide more information about the company's clinical drug trials in China.
Chairman John Moolenaar of the Select Committee on China has sent a letter to Secretary of Treasury Scott Bessent urging him to add biotechnology as a prohibited technology under the Comprehensive Outbound Investment National Security (COINS) Act of 2025. The request comes in response to a dangerous surge of American capital and knowledge into China’s biotechnology sector, including Bristol Myers Squibb’s recently announced $15 billion deal with China’s Hengrui Pharma that also transfers intellectual property to China.
Chairman John Moolenaar of the Select Committee on China, Chairman Bill Cassidy of the Senate Health, Education, Labor, and Pensions (HELP) Committee, Chairman Tim Walberg of the House Education and Workforce Committee, and Senator Jim Banks raised serious concerns following a new U.S.